Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma

Archives of Dermatology

Volumn 145, Issue 9, 2009, Pages 985-988

  Gardner, Jennifer M ^a,b   Evans, Katherine G ^a   Goldstein, Steven ^a   Kim, Ellen J ^a   Vittorio, Carmela C ^a   Rook, Alain H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CORTICOSTEROID; DENILEUKIN DIFTITOX; FUROSEMIDE; GAMMA INTERFERON; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE; PSORALEN; VORINOSTAT;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BULLOUS PEMPHIGOID; CASE REPORT; ELECTRON THERAPY; FEMALE; HUMAN; IMMUNOFLUORESCENCE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PUVA; RADIATION DERMATITIS; SKIN LYMPHOMA; T CELL LYMPHOMA; ULTRAVIOLET A RADIATION;

ANTIBODIES, ANTI-IDIOTYPIC; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOLLOW-UP STUDIES; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOGLOBULIN G; LYMPHOMA, T-CELL, CUTANEOUS; MIDDLE AGED; PEMPHIGOID, BULLOUS; SKIN NEOPLASMS;

EID: 70349319996     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.229     Document Type: Article

References (19)

1. Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T cell lymphoma. Clin Cancer Res. 2007;13(8):2318-2322. (Pubitemid 46698579)
2. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007;16(7):1111-1120. (Pubitemid 47074165)
3. Xu WS, Parmigiani RB, Marks PA, et al. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26(37):5541-5552. (Pubitemid 47255934)
4. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26(9):1351-1356.
5. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74(5):659-671.
6. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007;13(11):1299- 1307. (Pubitemid 350073591)
7. Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A. 2004;101(11):3921-3926. (Pubitemid 38381078)
8. James WD, Berger TG, Elston DM. Andrews' Diseases of the Skin: Clinical Dermatology. 10th ed. Philadelphia, PA: Sanders Elsevier; 2006.
9. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest. 2006;116(5):1159-1166.
10. Mutasim DF. Management of autoimmune bullous diseases: pharmacology and therapeutics. J Am Acad Dermatol. 2004;51(6):859-877. (Pubitemid 39592999)
11. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115(4):798-812. (Pubitemid 40489380)
12. Wood KJ, Feng G, Wei B, Sawitzki B, Bushell AR. Interferon gamma: friend or foe? Transplantation. 2007;84(1)(suppl):S4-S5. (Pubitemid 47067533)
13. Stern M, Buser AS, Lohri A, Tichelli A, Nissen-Druey C. Autoimmunity and malignancy in hematology: more than an association. Crit Rev Oncol Hematol. 2007;63(2):100-110. (Pubitemid 46994748)
14. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2069-2077. (Pubitemid 44877028)
15. Preesman AH, Toonstra J, Van der Putte SC, De Geer DB, Van Weelden H, Van Vloten WA. UV-B-induced bullous pemphigoid restricted to mycosis fungoides plaques. Clin Exp Dermatol. 1990;15(5):363-366. (Pubitemid 20277341)
16. Patterson JW, Ali M, Murray JC, Hazra TA. Bullous pemphigoid occurrence in a patient with mycosis fungoides receiving PUVA and topical nitrogen mustard therapy. Int J Dermatol. 1985;24(3):173-176. (Pubitemid 15106555)
17. Lin H-S, Hu C-Y, Chan H-Y, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol. 2007;150(7):862-872.
18. French AR, Yokoyama WM. Natural killer cells and autoimmunity. Arthritis Res Ther. 2004;6(1):8-14.
19. Brogdon JL, Xu Y, Szabo S, et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 2007;109(3):1123-1130. (Pubitemid 46220659)